Anzeige
Mehr »
Sonntag, 22.03.2026 - Börsentäglich über 12.000 News
Das "Next Butte?"-Setup in Montana - und es ist noch immer eine $15M-Story
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4LY | ISIN: US00773J2024 | Ticker-Symbol: 3920
Tradegate
19.03.26 | 20:45
36,600 Euro
+2,23 % +0,800
1-Jahres-Chart
SPYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
35,60035,80021.03.
35,20036,20020.03.

Aktueller Chart SPYRE THERAPEUTICS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
SPYRE THERAPEUTICS INC-Investoren interessieren sich auch für diese Wertpapiere
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...
► Artikel lesen
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of RapamycinPatent strengthens global intellectual property protection for QTORIN rapamycin, Palvella's lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesWAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...
► Artikel lesen
Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic MalformationsPrimary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged...
► Artikel lesen
Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big SwingsWASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen